Skip to main content
Fig. 1 | Journal of Neuroinflammation

Fig. 1

From: Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy

Fig. 1

Correlation between changes in the plasma IL-33 and regulatory T (Treg) cell frequencies and clinical response to IVIG therapy in GBS patients. a Temporal changes in the amount of IL-33 (pg/ml) in the plasma of ten Guillain-Barré syndrome patients before (week 0) and weeks 1, 2, and ≥4 following initiation of IVIG therapy. Statistical significance as determined by one-way ANOVA. ***P < 0.001, **P < 0.01, ns = not significant. b Correlation between the clinical response (MRC score) at different time points (weeks 1, 2, and ≥4) after initiation of IVIG therapy and the fold changes in plasma IL-33 at week 1. c Correlation between the clinical response (MRC score) at different time points (weeks 1, 2, and ≥4) after initiation of IVIG therapy and the fold changes in circulating Treg cells at week 1. Each symbol represents individual patient. r = Pearson correlation. p = statistical significance

Back to article page